$BMY News

BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook

Bristol Myers Squibb Q2 Earnings Call Highlights

Bristol-Myers Squibb's Catalyst Delays May Keep Stock Range-Bound, RBC Says

RBC Capital Maintains Sector Perform on Bristol-Myers Squibb, Raises Price Target to $64

BMY Q2 Earnings Call Highlights Growth Portfolio Momentum

JP Morgan Maintains Overweight on Bristol-Myers Squibb, Raises Price Target to $73

Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $59

Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $65

Guggenheim Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $75

Bristol Myers Squibb (BMY) Earnings Beat And Higher Outlook Put Valuation Back In Focus

Truist Securities Reiterates Buy on Bristol-Myers Squibb

Bristol-Myers Squibb Company Q2 2026 Earnings Call Summary

Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript

Bristol-Myers Squibb Co (BMY) (Q2 2026) Earnings Call Highlights: Growth Portfolio Surges 14%, ...

Bristol-Myers Boosts 2026 Guidance on Portfolio Strength

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings Beat

Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb: Upgrading To Buy On Positive Q2 Earnings, Long-Term Outlook